CN104870440B - 双环杂环化合物及其治疗用途 - Google Patents

双环杂环化合物及其治疗用途 Download PDF

Info

Publication number
CN104870440B
CN104870440B CN201380066425.6A CN201380066425A CN104870440B CN 104870440 B CN104870440 B CN 104870440B CN 201380066425 A CN201380066425 A CN 201380066425A CN 104870440 B CN104870440 B CN 104870440B
Authority
CN
China
Prior art keywords
methyl
alkyl
bases
dimethyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380066425.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104870440A (zh
Inventor
G.切萨里
C.N.约翰逊
L.W.佩奇
A.米莱马吉
S.霍华德
G.萨克斯蒂
T.D.海格特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Therapeutics Ltd
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Publication of CN104870440A publication Critical patent/CN104870440A/zh
Application granted granted Critical
Publication of CN104870440B publication Critical patent/CN104870440B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380066425.6A 2012-10-19 2013-10-18 双环杂环化合物及其治疗用途 Active CN104870440B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261716089P 2012-10-19 2012-10-19
US61/716089 2012-10-19
GB1218864.5 2012-10-19
GBGB1218864.5A GB201218864D0 (en) 2012-10-19 2012-10-19 Bicyclic heterocycle compounds and their uses in therapy
PCT/GB2013/052721 WO2014060768A1 (en) 2012-10-19 2013-10-18 Bicyclic heterocycle compounds and their uses in therapy

Publications (2)

Publication Number Publication Date
CN104870440A CN104870440A (zh) 2015-08-26
CN104870440B true CN104870440B (zh) 2018-10-19

Family

ID=47359191

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380066425.6A Active CN104870440B (zh) 2012-10-19 2013-10-18 双环杂环化合物及其治疗用途

Country Status (10)

Country Link
US (1) US9663512B2 (https=)
EP (1) EP2909197B1 (https=)
JP (1) JP6324976B2 (https=)
KR (1) KR102299832B1 (https=)
CN (1) CN104870440B (https=)
CA (1) CA2888112C (https=)
DK (1) DK2909197T3 (https=)
ES (1) ES2794009T3 (https=)
GB (1) GB201218864D0 (https=)
WO (1) WO2014060768A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2017253560B2 (en) 2016-04-20 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
CN106265764B (zh) 2016-08-18 2018-03-16 广州威溶特医药科技有限公司 Iap抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
US20210361774A1 (en) 2018-10-16 2021-11-25 Dana-Farber Cancer Institute, Inc. Degraders of wild-type and mutant forms of lrrk2
EP3947368B1 (en) 2019-04-04 2025-09-03 Dana-Farber Cancer Institute, Inc. Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
EP4146648A1 (en) 2020-05-04 2023-03-15 Otsuka Pharmaceutical Co., Ltd. Iap antagonist compounds and intermediates and methods for synthesizing the same
EP4490159A4 (en) * 2022-03-11 2025-08-20 Ascentage Pharma Suzhou Co Ltd TRICYCLIC HETEROCYCLIC COMPOUNDS AS IAP ANTAGONISTS
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101595121A (zh) * 2006-10-12 2009-12-02 诺瓦提斯公司 作为iap抑制剂的吡咯烷衍生物
WO2012143726A1 (en) * 2011-04-21 2012-10-26 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080330A (en) 1975-06-23 1978-03-21 Delmar Chemicals Limited Phenylindolines and process for their production
DE3822792C2 (de) 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
TW218875B (https=) 1992-03-09 1994-01-11 Takeda Pharm Industry Co Ltd
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
PT778277E (pt) 1995-12-08 2003-11-28 Pfizer Derivados heterociclicos substituidos como antagonistas do crf
PT892780E (pt) 1996-02-22 2003-02-28 Bristol Myers Squibb Pharma Co Analogos de m-amidino fenilo como inibidores do factor xa
EP0944388A4 (en) 1996-04-03 2001-08-16 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
JP2000513375A (ja) 1996-06-28 2000-10-10 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプター拮抗薬プロドラッグ
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0975593A1 (en) 1997-04-18 2000-02-02 Smithkline Beecham Plc Indole derivatives having combined 5ht1a, 5ht1b and 5ht1d receptor antagonist activity
AU7526798A (en) 1997-04-18 1998-11-27 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
US6084098A (en) 1999-02-26 2000-07-04 Neurogen Corporation Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands
BR9909277A (pt) 1998-03-31 2001-10-16 Acadia Pharm Inc Compostos com atividade em receptores muscarìnicos
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6608084B1 (en) 1998-08-26 2003-08-19 Aventis Pharma Ltd. Aza-bicycles which modulate the inhibition of cell adhesion
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
AU3555200A (en) 1999-03-17 2000-10-04 F. Hoffmann-La Roche Ag Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators
GB9929552D0 (en) 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
US6534535B1 (en) 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6878712B1 (en) 1999-09-04 2005-04-12 Astrazeneca Ab Amides as inhibitors for pyruvate dehydrogenase
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
CA2433090A1 (en) 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
WO2002080853A2 (en) 2001-04-09 2002-10-17 Bristol-Myers Squibb Company Fused heterocyclic inhibitors of factor xa
EP1389194A2 (en) 2001-04-27 2004-02-18 Vertex Pharmaceuticals Incorporated Inhibitors of bace
US20050245537A1 (en) 2002-04-24 2005-11-03 Noboru Tsuchimori Use of compounds having ccr antagonism
BRPI0408136A (pt) 2003-03-07 2006-03-01 Astellas Pharma Inc derivados heterocìclicos contendo nitrogênio tendo estirila 2,6-dissubstituìda
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
AU2004266233A1 (en) 2003-08-13 2005-03-03 Amgen, Inc. Melanin concentrating hormone receptor antagonist
TW200524887A (en) 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
WO2006010118A2 (en) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
WO2006032987A1 (en) 2004-09-23 2006-03-30 Pfizer Products Inc. Indoline compounds and their use in the treatment of arteriosclerosis
DK1836201T4 (da) 2004-12-20 2013-11-11 Genentech Inc Pyrrolidininhibitorer af IAP.
JP4955009B2 (ja) 2005-11-11 2012-06-20 エフ．ホフマン−ラ ロシュ アーゲー 凝固因子Ｘａの阻害剤としての炭素環式縮合環アミン
CA2634699A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
FR2896504B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
GB0602335D0 (en) 2006-02-07 2006-03-15 Remynd Nv Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
JP2010520293A (ja) 2007-03-07 2010-06-10 アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド 複素環式部分を含有するメタロプロテアーゼ阻害剤
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
CA2712604A1 (en) 2008-01-24 2009-07-30 Tetralogic Pharmaceutical Corporation Iap inhibitors
WO2009147476A1 (en) 2008-06-02 2009-12-10 Matrix Laboratories Ltd. Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation
WO2010011666A2 (en) 2008-07-21 2010-01-28 University Of South Florida Indoline scaffold shp-2 inhibitors and cancer treatment method
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010121212A2 (en) 2009-04-17 2010-10-21 H. Lee Moffit Cancer Center And Research Institute, Inc. Indoline scaffold shp-2 inhibitors and method of treating cancer
CA2761009A1 (en) 2009-05-04 2010-11-11 Plexxikon, Inc. Compounds and methods for inhibition of renin, and indications therefor
AU2010254056A1 (en) 2009-05-28 2011-12-15 Tetralogic Pharmaceuticals Corp. IAP inhibitors
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
CA2850757A1 (en) 2011-10-03 2013-04-11 The Trustees Of Columbia University In The City Of New York Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
ES2802251T3 (es) 2012-01-06 2021-01-18 Novartis Ag Compuestos heterocíclicos y métodos para su uso
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
US10087151B2 (en) 2014-01-09 2018-10-02 The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101595121A (zh) * 2006-10-12 2009-12-02 诺瓦提斯公司 作为iap抑制剂的吡咯烷衍生物
WO2012143726A1 (en) * 2011-04-21 2012-10-26 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy

Also Published As

Publication number Publication date
JP2015534975A (ja) 2015-12-07
US20150266873A1 (en) 2015-09-24
US9663512B2 (en) 2017-05-30
GB201218864D0 (en) 2012-12-05
CA2888112A1 (en) 2014-04-24
EP2909197A1 (en) 2015-08-26
ES2794009T3 (es) 2020-11-17
DK2909197T3 (da) 2020-05-25
CN104870440A (zh) 2015-08-26
JP6324976B2 (ja) 2018-05-16
CA2888112C (en) 2021-03-30
WO2014060768A1 (en) 2014-04-24
EP2909197B1 (en) 2020-03-04
KR20150072436A (ko) 2015-06-29
KR102299832B1 (ko) 2021-09-07

Similar Documents

Publication Publication Date Title
CN104870440B (zh) 双环杂环化合物及其治疗用途
US11643410B2 (en) Bicyclic heterocycle compounds and their uses in therapy
CN104870442B (zh) 双环杂环化合物及其治疗用途
CN104870441B (zh) 双环杂环化合物及其治疗用途
JP6321020B2 (ja) 二環式複素環化合物およびそれらの治療での使用
HK40084234A (en) Bicyclic heterocycle compounds and their uses in therapy
HK40084234B (zh) 双环杂环化合物及其治疗用途
HK1262092B (en) Bicyclic heterocycle compounds and their uses in therapy
HK1262092A1 (en) Bicyclic heterocycle compounds and their uses in therapy

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant